Business / Finance

RSS

Haemonetics second quarter net revenues increase 8% to $179.4 million

Haemonetics Corporation today reported second quarter 2012 GAAP net revenues of $179.4 million, up 8%, net income of $13.9 million, down 35%, and earnings per share of $0.54, down 36%. Excluding transformation costs and contingent consideration income, adjusted second quarter net income was $18.7 million, down 7%, and adjusted earnings per share was $0.72, down 9%. Excluding currency impacts, net revenue was up 6% in the quarter.

31 Oct 2011

Auxilium reports net revenues of $66.7 million for third quarter 2011

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced financial results and operational highlights for the quarter ended September 30, 2011.

31 Oct 2011

Pacira's third quarter total revenues decrease to $4.0 million

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced financial results for the third quarter ended September 30, 2011 and provided an update on the U.S. Food and Drug Administration's (FDA) approval of EXPAREL and the commercial strategy to support the product launch.

31 Oct 2011

Humana third quarter consolidated revenues increase 11% to $9.30 billion

Humana Inc. today reported diluted earnings per common share (EPS) for the quarter ended September 30, 2011 (3Q11) of $2.67, compared to $2.32 per share for the quarter ended September 30, 2010.

31 Oct 2011

Eye Shelter, Menicon sign SOLO-care contact lens marketing agreement

Menicon Holdings BV and Eye Shelter SA, a wholly owned subsidiary of Laboratoires Thea, a France-based independent ophthalmic group, announced on October 31 that Menicon is to become Eye Shelter's exclusive partner to market the SOLO-care (R) contact lens solutions range in member states of the European Economic Area and Canada.

31 Oct 2011

Coventry reports operating revenues of $3.0B for third quarter 2011

Coventry Health Care, Inc. today reported consolidated operating results for the quarter ended September 30, 2011. Operating revenues totaled $3.0 billion for the quarter with net earnings of $122.7 million, or earnings per diluted share (EPS) of $0.84.

29 Oct 2011

Sorin Group third quarter revenues decrease 2.1% to €171.4 million

Sorin Group: Revenues of €171.4 million, a 2.1% decline (-4.9% as reported) over the same period last year.

29 Oct 2011

Cigna third quarter adjusted income from operations increases to $325 million

Cigna Corporation today reported third quarter 2011 results that included strong revenue and earnings from each of our ongoing businesses, reflecting continued effective execution of the fundamentals supporting our long-term growth strategy.

29 Oct 2011

Merck third quarter global sales increase 8% to $12.0 billion

Merck, known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2011.

29 Oct 2011

HMS third quarter revenue increases 15.4% to $92.4 million

HMS Holdings Corp. today announced its financial results for the third quarter of 2011.

29 Oct 2011

Spherix closes private placement transaction

Spherix Incorporated – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies – today announced the closing of previously announced agreements to sell $1.25 million of shares of its common stock together with warrants to purchase additional shares of its common stock in a private placement transaction.

29 Oct 2011

Intrexon acquires Immunologix

SCRA, on behalf of its SC Launch program, today announced that Portfolio Company Immunologix has been acquired by Virginia-based synthetic biology company Intrexon Corporation. The Charleston-based Immunologix team is now part of Intrexon's Protein Production Division.

29 Oct 2011

Standard Register reports revenue of $157.5 million for third quarter 2011

Standard Register today announced its financial results for the third quarter. The Company reported revenue of $157.5 million and a net profit of $8.4 million, or $0.29 per diluted share.

29 Oct 2011

Pfizer acquires Icagen

Pfizer Inc. announced today that it has completed its acquisition of Icagen, Inc., through the merger of its wholly owned subsidiary, Eclipse Acquisition Corp., with and into Icagen. Icagen is now a wholly-owned subsidiary of Pfizer.

29 Oct 2011

LifePoint Hospitals third quarter revenues increase 5.4% to $877.2 million

LifePoint Hospitals, Inc. today announced results for the third quarter and nine months ended September 30, 2011.

28 Oct 2011

Biogen Idec third quarter revenues increase 11% to $1.3 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its third quarter 2011 results.

28 Oct 2011

Amerigroup reports net income of $48.1 million for third quarter 2011

Amerigroup Corporation today announced that net income for the third quarter of 2011 was $48.1 million, or $0.96 per diluted share, versus net income of $84.3 million, or $1.68 per diluted share, for the third quarter of 2010 and compared to $44.3 million, or $0.83 per diluted share, for the second quarter of 2011.

28 Oct 2011